Eton Pharmaceuticals (ETON) CEO Sean Brynjelsen Receives RSU Award

What Happened
Sean Brynjelsen, President & CEO and a director of Eton Pharmaceuticals, was granted 128,985 performance-vested restricted stock units (RSUs) on July 31, 2026. The award was granted at $0.00 (derivative award) and represents the right to one share of common stock per RSU. The RSUs vest in full only if Eton’s common stock closes at or above $72.36 for one trading day at any time before July 31, 2029; if that market condition is not met by that date the award is forfeited.

Key Details

• Transaction date: 2026-07-31; transaction code: A (award/grant); shares: 128,985; price: $0.00 (derivative).
• Each RSU equals the right to one share; the number reported is the maximum and only number issuable under the award (no threshold/range).
• Vesting condition: single-day closing price ≥ $72.36 anytime before 7/31/2029; if unmet, award is forfeited on 7/31/2029.
• Filing remark: the reporting person authorized another to file this Form 4 on their behalf; no late-filing indication in the report.

Context
This is a performance-based equity compensation grant (derivative award), not an open-market purchase or sale. It creates potential future dilution if the market condition is met and the RSUs convert to shares; it does not represent an immediate cash outlay or sale by the insider. As with other performance RSUs, vesting is contingent on a stock-price target rather than time-based service only.